Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,352 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacodynamic and pharmacokinetic profile of RBx 343E48F0: a novel, long acting muscarinic receptor antagonist.
Gupta S, Malhotra S, Sinha S, Singh SK, Singh RK, Krishna S, Chhabra P, Chaira T, Kannayiram J, Sharma P, Aeron S, Kaur J, Kumar N, Sattigeri J, Shirumalla RK, Paliwal J, Dastidar SG, Cliffe IA, Ray A, Bhatnagar P. Gupta S, et al. Among authors: ray a. Eur J Pharmacol. 2011 May 11;658(2-3):219-28. doi: 10.1016/j.ejphar.2011.02.024. Epub 2011 Mar 1. Eur J Pharmacol. 2011. PMID: 21371471
RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S, Roy S, Sethi S, Benjamin B, Sundaram S, Khanna V, Kandalkar SR, Pal C, Kant R, Patra AK, Rayasam G, Mittra S, Saini KS, Paliwal J, Chugh A, Ahmed S, Sattigeri J, Cliff I, Ray A, Bansal VS, Bhatnagar PK, Davis JA. Singh S, et al. Among authors: ray a. Eur J Pharmacol. 2011 Feb 10;652(1-3):157-63. doi: 10.1016/j.ejphar.2010.06.001. Epub 2010 Jun 9. Eur J Pharmacol. 2011. PMID: 20540938
Pharmacology of a novel, orally active PDE4 inhibitor.
Dastidar SG, Ray A, Shirumalla R, Rajagopal D, Chaudhary S, Nanda K, Sharma P, Seth MK, Balachandran S, Gupta N, Palle V. Dastidar SG, et al. Among authors: ray a. Pharmacology. 2009;83(5):275-86. doi: 10.1159/000209608. Epub 2009 Mar 25. Pharmacology. 2009. PMID: 19321962
Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
Tandon R, Kapoor S, Vali S, Senthil V, Nithya D, Venkataramanan R, Sharma A, Talwadkar A, Ray A, Bhatnagar PK, Dastidar SG. Tandon R, et al. Among authors: ray a. Eur J Pharmacol. 2011 Sep 30;667(1-3):56-65. doi: 10.1016/j.ejphar.2011.04.066. Epub 2011 May 30. Eur J Pharmacol. 2011. PMID: 21640718
RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy.
Tandon R, Senthil V, Nithya D, Pamidiboina V, Kumar A, Malik S, Chaira T, Diwan M, Gupta P, Venkataramanan R, Malik R, Das B, Dastidar SG, Cliffe I, Ray A, Bhatnagar PK. Tandon R, et al. Among authors: ray a. Eur J Pharmacol. 2013 Jul 5;711(1-3):19-26. doi: 10.1016/j.ejphar.2013.04.016. Epub 2013 Apr 29. Eur J Pharmacol. 2013. PMID: 23639757
3,352 results